DiaMedica Therapeutics Inc.
NasdaqCM:DMAC Lagerbericht
Marktkapitalisierung: US$183.8m
DiaMedica Therapeutics Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6 DiaMedica TherapeuticsDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -14.4% zurückgegangen, während in der Branche Biotechs die Gewinne wachsen. Die Umsätze sind rückläufig mit einer durchschnittlichen Rate von 109.2% pro Jahr.
Wichtige Informationen
-14.4%
Wachstumsrate der Gewinne
Biotechs Wachstum der Industrie 17.0% Wachstumsrate der Einnahmen -109.2% Eigenkapitalrendite -37.3% Netto-Marge n/a Nächste Ertragsaktualisierung 13 Nov 2024
Jüngste Aktualisierungen vergangener Leistungen
DiaMedica Therapeutics Inc. to Report Q3, 2024 Results on Nov 13, 2024 Nov 06
DiaMedica Therapeutics Inc. to Report Q2, 2024 Results on Aug 07, 2024 Aug 01
DiaMedica Therapeutics Inc. to Report Q1, 2024 Results on May 08, 2024 May 03
DiaMedica Therapeutics Inc. to Report Q3, 2023 Results on Nov 13, 2023 Nov 07
DiaMedica Therapeutics Inc. to Report Q2, 2023 Results on Aug 14, 2023 Aug 09
DiaMedica Therapeutics Inc. to Report Q1, 2023 Results on May 15, 2023 May 09
Alle Updates anzeigen
DiaMedica Therapeutics Inc. to Report Q3, 2024 Results on Nov 13, 2024 Nov 06
DiaMedica Therapeutics Inc. Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia Oct 09
DiaMedica Therapeutics Inc. to Report Q2, 2024 Results on Aug 07, 2024 Aug 01
New minor risk - Shareholder dilution Jul 07 DiaMedica Therapeutics Inc. announced that it has received $11.8 million in funding Jul 03
DiaMedica Therapeutics Inc. announced that it has received $11.8 million in funding Jul 01
DiaMedica Therapeutics Inc. announced that it expects to receive $11.8 million in funding Jun 27
DiaMedica Therapeutics Inc. Plans to Expand Its Clinical Trials into Preeclampsia Jun 26
New minor risk - Market cap size Jun 09
New minor risk - Share price stability Jun 07
DiaMedica Therapeutics Inc. Elects Rick Pauls as Director May 25
DiaMedica Therapeutics Inc. to Report Q1, 2024 Results on May 08, 2024 May 03
No longer forecast to breakeven Apr 24
DiaMedica Therapeutics Inc. Announces First Patient Dosed in Relaunch of Its Pivotal Phase /3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke Apr 18
New minor risk - Market cap size Apr 12
New major risk - Revenue and earnings growth Apr 11
Price target decreased by 16% to US$7.00 Mar 21
DiaMedica Therapeutics Inc., Annual General Meeting, May 22, 2024 Feb 13
DiaMedica Therapeutics Inc. Appoints Dr. Lorianne Masuoka as Chief Medical Officer Jan 22
DiaMedica Therapeutics Inc. to Report Q3, 2023 Results on Nov 13, 2023 Nov 07
DiaMedica Therapeutics Inc. Announces the Appointment of Ambarish Shah as Chief Technology Officer Sep 13
DiaMedica Therapeutics Inc. to Report Q2, 2023 Results on Aug 14, 2023 Aug 09
New major risk - Share price stability Jul 20
New minor risk - Shareholder dilution Jun 27
Chief Business Officer recently bought US$150k worth of stock Jun 27
Price target increased by 11% to US$8.33 Jun 26 DiaMedica Therapeutics Inc. announced that it expects to receive $37.43878 million in funding
Price target decreased by 13% to US$7.00 Jun 22
Diamedica Therapeutics Announces Appointment of Richard Kuntz to the Board of Directors May 31
Diamedica Therapeutics Inc. Files Complete Clinical Hold Response with the U.S. Food and Drug Administration Regarding the Status of the Remedy2 Study May 24
Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation May 16
DiaMedica Therapeutics Inc. to Report Q1, 2023 Results on May 15, 2023 May 09
Insider recently bought US$750k worth of stock Apr 13
No longer forecast to breakeven Mar 31
We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely Jan 12
Forecast to breakeven in 2025 Dec 31
Independent Director recently bought US$80k worth of stock Dec 03
Price target decreased to US$10.67 Nov 16
DiaMedica Therapeutics Inc. Provides Update on Remedy2 Trial Oct 28
DiaMedica Therapeutics Appoints Julie Daves as SVP, Clinical Development Operations Sep 15
DiaMedica Therapeutics Inc. to Report Q2, 2022 Results on Aug 10, 2022 Aug 05
No longer forecast to breakeven Jul 08
DiaMedica Therapeutics Announces Clinical Hold of its Phase 2/3 ReMEDy2 Clinical Trial for DM199 Jul 07
FDA puts DiaMedica's phase 2/3 trial for its stroke treatment DM199 on clinical hold Jul 06
We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate Jun 16
Diamedica Therapeutics Inc. Announces Resignation of Harry Alcorn, Jr. , Senior Vice President of Clinical Operations May 28
Price target decreased to US$13.25 Apr 27
High number of new and inexperienced directors Apr 27
High number of new and inexperienced directors Apr 13
Price target decreased to US$15.80 Mar 16
DiaMedica Therapeutics Inc., Annual General Meeting, May 18, 2022 Feb 12
DiaMedica Therapeutics Inc. Appoints Dominic Cundari as Chief Commercial Officer Feb 03
Price target increased to US$20.00 Feb 03
We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely Jan 04
Forecast to breakeven in 2024 Jan 02
DiaMedica: Proven Stroke Drug In Asia, Headed To The U.S. Nov 05
Price target decreased to US$20.40 Sep 28
Chief Medical Officer recently bought US$57k worth of stock Sep 16
DiaMedica Therapeutics Inc. Initiates Pivotal Trial of DM199 for the Treatment of Acute Ischemic Stroke Sep 15
Chief Medical Officer recently bought US$64k worth of stock Aug 17
DiaMedica Therapeutics Inc. Announces Positive Interim Results from Phase 2 REDUX Study in CKD Jun 30
DiaMedica Therapeutics Inc.(NasdaqCM:DMAC) dropped from Russell 3000E Value Index Jun 28
DiaMedica: Undercovered Stroke Drug Company With Decent Data Jun 13
DiaMedica Therapeutics Announces FDA Clearance of IND Application to Initiate Phase 2/3 Clinical Trial for DM199 for Acute Ischemic Stroke May 18
We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth May 01
Price target increased to US$25.00 Mar 18
DiaMedica Therapeutics Inc. to Report Q4, 2020 Results on Mar 10, 2021 Mar 04
DiaMedica Therapeutics Inc., Annual General Meeting, May 25, 2021 Feb 23
New 90-day high: US$10.42 Feb 18
Could The DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Ownership Structure Tell Us Something Useful? Feb 13
New 90-day high: US$10.30 Jan 20
We're Not Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Jan 09
Price target raised to US$18.25 Jan 09
DiaMedica Therapeutics Announces Enrollment of Last Patient in Diabetic Kidney Disease Cohort of Phase 2 REDUX CKD Study Dec 17
DiaMedica Therapeutics Inc. Announces Successful Type B Meeting with FDA for the Study of DM199 in Patients with Acute Ischemic Stroke Dec 11
DiaMedica Therapeutics Inc. 2020 Q3 - Results - Earnings Call Presentation Nov 06
DiaMedica Therapeutics Inc. to Report Q3, 2020 Results on Nov 04, 2020 Oct 29
DiaMedica Therapeutics Inc. Announces First Patients Dosed in Diabetic Kidney Disease Cohort in Phase II REDUX CKD Clinical Study Sep 15 DiaMedica Therapeutics Inc. to Report Q2, 2020 Results on Aug 11, 2020
Aufschlüsselung der Einnahmen und Ausgaben
Wie DiaMedica Therapeutics Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie NasdaqCM:DMAC Einnahmen, Ausgaben und Erträge (USD Millions) Datum Einnahmen Umsatz Allgemeine und Verwaltungskosten F&E-Ausgaben 30 Jun 24 0 -20 8 15 31 Mar 24 0 -19 8 13 31 Dec 23 0 -19 8 13 30 Sep 23 0 -18 8 12 30 Jun 23 0 -17 7 10 31 Mar 23 0 -15 7 9 31 Dec 22 0 -14 6 8 30 Sep 22 0 -13 6 7 30 Jun 22 0 -14 5 8 31 Mar 22 0 -13 5 8 31 Dec 21 0 -14 5 9 30 Sep 21 0 -15 5 10 30 Jun 21 0 -14 5 10 31 Mar 21 0 -13 5 9 31 Dec 20 0 -12 4 8 30 Sep 20 0 -11 4 8 30 Jun 20 0 -10 4 6 31 Mar 20 0 -10 4 7 31 Dec 19 0 -11 4 8 30 Sep 19 0 -10 3 6 30 Jun 19 1 -9 3 7 31 Mar 19 1 -8 3 6 31 Dec 18 1 -6 2 5 30 Sep 18 1 -5 3 4 30 Jun 18 0 -4 2 3 31 Mar 18 0 -4 2 3 31 Dec 17 0 -4 1 3 30 Sep 17 0 -4 1 3 30 Jun 17 0 -4 1 3 31 Mar 17 0 -3 1 3 31 Dec 16 0 -2 1 2 30 Sep 16 0 -2 1 2 30 Jun 16 0 -2 1 1 31 Mar 16 0 -1 0 1 31 Dec 15 0 -2 0 1 30 Sep 15 0 -2 1 1 30 Jun 15 0 -2 1 1 31 Mar 15 0 -3 1 2 31 Dec 14 0 -5 1 3 30 Sep 14 0 -5 1 4 30 Jun 14 0 -6 1 5 31 Mar 14 0 -7 1 6
Qualität der Erträge: DMAC ist derzeit unrentabel.
Wachsende Gewinnspanne: DMAC ist derzeit unrentabel.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: DMAC ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 14.4% pro Jahr zugenommen.
Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von DMAC verglichen werden, da das Unternehmen derzeit nicht profitabel ist.
Erträge im Vergleich zur Industrie: DMAC ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Biotechs (16.6%) erschwert.
Eigenkapitalrendite
Hohe Eigenkapitalrendite: DMAC hat eine negative Eigenkapitalrendite (-37.26%), da es derzeit unrentabel ist.
Rendite auf das eingesetzte Kapital
Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
